- Investing Ideas
- German Pharmaceuticals & Biotech Healthy potentially undervalued
German Pharmaceuticals & Biotech Healthy potentially undervalued
Results
5
Companies which are potentially undervalued and in an acceptable financial position.
5 companies
Merck KGaA
Market Cap: €47.3b
Operates as a science and technology company in Europe, North America, Latin America, Middle East and Africa, and the Asia Pacific.
MRK
€108.20
7D
0.5%
1Y
-20.5%
SCHOTT Pharma KGaA
Market Cap: €2.0b
Develops, manufactures, and sells drug containment solutions and delivery systems for injectable drugs for pharma, biotech, and life science industries worldwide.
1SXP
€13.48
7D
-1.9%
1Y
-45.7%
Bayer
Market Cap: €39.5b
Operates as a life science company in Europe, the Middle East, Africa, Germany, Switzerland, North America, the United States, the Asia Pacific, China, Latin America, and Brazil.
BAYN
€40.09
7D
6.7%
1Y
68.5%
Evotec
Market Cap: €751.3m
Operates as a drug discovery and development company in the United States, Germany, France, the United Kingdom, Switzerland, and internationally.
EVT
€4.26
7D
-19.1%
1Y
-34.2%
Formycon
Market Cap: €341.3m
A biotechnology company, develops biosimilar drugs in Germany and Switzerland.
FYB
€19.32
7D
0.8%
1Y
-29.5%